Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer

Lorente, David; Castro, Elena; Lozano, Rebeca; Puente, Javier; Romero-Laorden, Nuria; Rodríguez‐Vida, Alejo; Laínez, Núria; Villatoro, R.; Llácer, Casilda; Cattrini, Carlo; Hernández, A.; Domènech, Montserrat; Zambrana, Francisco; Almagro, Elena; Luque, Raquel; Martínez, E.; López-Campos, Fernando; González, Belen; Mendez-Vidal, María José; Medina, Ana Maria; Piulats, Josep María; Olmos, David

doi:10.1016/j.eururo.2020.02.025

Cited by 9 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, despite adjustments for variables including these factors, the results of the propensity score‐matched cohorts were similar to those of the overall cohort; there was no significant difference in OS between the two groups, while the AA group had a shorter PFS2. Moreover, although PFS2 has been reported to be likely associated with OS, 35 our results were inconsistent with findings from those of previous reports. These facts suggest that the proper introduction of subsequent therapy may make up for the difference in the effects up to the second‐line treatment as a result.…”

Section: Discussioncontrasting

confidence: 99%

“…17,18,33,33,34 In our study, despite adjustments for variables including these factors, the results of the propensity score-matched cohorts were similar to those of the overall cohort; there was no significant difference in OS between the two groups, while the AA group had a shorter PFS2. Moreover, although PFS2 has been reported to be likely associated with OS, 35 disease. 15,17,18,28,28,33,34 Our results do not suggest that ART should be prioritized over DTX; rather, the implication of this study is that ART-to-ART sequential therapy is a promising option for appropriately selected patients in actual clinical practice.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The clinical benefit of sequential therapy with androgen receptor axis‐targeted agents alone in patients with castration‐resistant prostate cancer: A propensity score‐matched comparison study

et al. 2020

View full text Add to dashboard Cite

Background: The optimal sequential therapy for castration-resistant prostate cancer (CRPC) remains unknown. In recent years, some doubts have emerged regarding the clinical benefit of sequential therapy with androgen receptor axistargeted agents (ART) such as abiraterone (ABI) or enzalutamide (ENZ) for patients with CRPC. We compared the effect of ART-to-ART (AA) sequential therapy after castration resistance with that of docetaxel (DTX)-combined sequential therapy (ART to DTX or DTX to ART) in patients with CRPC. Methods: We retrospectively identified and analyzed the data of 315 patients with CRPC treated in our seven affiliated institutions between 2009 and 2019. All patients received either DTX or ART (ABI or ENZ) as the first-or second-line therapy after castration resistance. We compared the overall survival (OS) and the second progression-free survival (PFS2), calculated from the initiation of first-line therapy after castration resistance, between the AA sequence group and the DTX-combined sequence group. PFS2 was defined as the period from the start of first-line treatment after castration resistance to progression on second-line treatment. To minimize selection bias from possible confounders, we performed propensity score matching using one-to-one nearest neighbor matching without replacement. Results: Overall, 106 and 209 patients were administered the AA sequential therapy and DTX-combined sequential therapy, respectively. The clinicopathological variables of patients were well balanced after propensity score matching, and there were no significant differences between the two groups. In the propensity scorematched cohort, OS was not significantly different between the two groups (median, 37.9 vs. 45.4 months; hazard ratio [HR], 1.10; 95% confidence interval [CI], 0.68-1.79; p = .701), while PFS2 was significantly shorter in the AA group than in

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The clinical benefit of sequential therapy with androgen receptor axis‐targeted agents alone in patients with castration‐resistant prostate cancer: A propensity score‐matched comparison study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This possibility was tested in a recent analysis of data from PROREPAIR-B that included 419 patients with mCRPC with or without DNA repair germline mutations. PFS2 was significantly associated with OS, whether the PFS2 was clinical, radiographic or biochemical and was a better indicator of treatment benefit than PFS (35).…”

Section: Discussionmentioning

confidence: 97%

Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors

et al. 2020

View full text Add to dashboard Cite

Background: Using progression-free survival (PFS)2, time from randomization to 2nd disease progression or death, is proposed as a surrogate for overall survival (OS) in oncology clinical trials. We used published data from solid tumor trials to assess whether PFS2 and OS are correlated. Methods: A literature search identified studies that reported PFS, PFS2, and OS. Two reviewers screened for eligibility, and documented PFS2, PFS or time from 1st to 2nd disease progression or death and OS. Correlation between PFS2 and OS was assessed using: (1) Kendall's Tau + Pearson's correlation coefficient in randomized controlled trials (RCTs); (2) Meta-analysis with the random effects model to compute the pooled correlation of PFS2 and OS. Results: Overall, 133 studies met search criteria, 15 (28 arms) had complete PFS2 and OS data in ovarian, gastric, colorectal, prostate, lung, renal and breast cancers. A positive correlation for PFS2 and OS was found for all 15 studies (Kendall's Tau = 0.7 [95% CIs 0.54, 0.78]); 10 RCTs (Pearson's correlation coefficient = 0.86); and metaanalysis from 7 trials (pooled Spearman's correlation coefficient = 0.84 [p = 0.0001; 95% CIs 0.71, 0.96]). Conclusions: In this retrospective analysis PFS2 strongly correlates with OS supporting the use of PFS2 to measure long-term clinical benefit when OS cannot be assessed.

show abstract

“…It has been speculated that it could be a more precise surrogate of the benefit of sequence therapy than PFS. 24 In a contemporary meta‐analysis of 15 studies on different tumor entities including PCa, Chowdhury and colleagues demonstrated that PFS2 strongly correlated with OS proposing its usage before OS data get mature or if OS cannot be assessed. 22 Using the data of the PROREPAIR‐B study which investigated the impact of germline DNA repair mutations on the outcomes of patients with mCRPC, 25 Lorente and coauthors observed that PFS2 outperformed PFS1 as a predictor of OS.…”

Section: Discussionmentioning

confidence: 99%

“…This endpoint is currently gaining increasing attention in clinical trials. It has been speculated that it could be a more precise surrogate of the benefit of sequence therapy than PFS 24 . In a contemporary meta‐analysis of 15 studies on different tumor entities including PCa, Chowdhury and colleagues demonstrated that PFS2 strongly correlated with OS proposing its usage before OS data get mature or if OS cannot be assessed 22 .…”

Section: Discussionmentioning

confidence: 99%

A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer

Tsaur¹,

Heidegger

Bektic

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

show abstract

Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer

Cited by 9 publications

References 9 publications

The clinical benefit of sequential therapy with androgen receptor axis‐targeted agents alone in patients with castration‐resistant prostate cancer: A propensity score‐matched comparison study

The clinical benefit of sequential therapy with androgen receptor axis‐targeted agents alone in patients with castration‐resistant prostate cancer: A propensity score‐matched comparison study

Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors

A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer

Contact Info

Product

Resources

About